Системные гипертензии

Расширенный поиск

Эффективность и безопасность современных мочегонных препаратов у пациентов с артериальной гипертонией осложненного течения

Об авторе

И. Е. Чазова
РКНПК МЗ и СР РФ, Москва

Список литературы

1. Neaton J.D, Grimm R.H, Prineas R.J et al. Treatment of mild hypertension study. JAMA 1993; 270: 713–24.

2. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high – risk hypertensive patients randomized to angiotensin – converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981–97.

3. SHEP cooperative research group. Prevention of stroke by antihypertesive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64.

4. Dahlof B, Lindholm L.H, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP – Hypertension). Lancet 1991; 338: 1281–5.

5. Medical research counsil working party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97–104.

6. Medical research counsil working party. Medical research counsil trial to treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12.

7. Леонова М.В., Белоусов Д.Ю., аналитическая группа исследования ПИФАГОР. Первое российское фармакоэпидемиологическое исследование артериальной гипертонии. Качествен. клин. практика. 2002; 3: 47–53.

8. Brown M.J, Palmer C.R, Castaigne A et al. Morbidity and mortality in patients randomized to double – blind treatment with a long – acting calcium – channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment. Lancet 2000; 356: 366–72.

9. Hansson L. Sustained release formulations in hypertension: pharmacokinetic innovations with indapamide SR 1.5 mg and related clinical implications. Clin Pharm 1999; 37: 1–38.

10. Ambrosioni E, Safar M, Degaute J-P et al. Low – dose antihypertesive therapy with 1.5 mg sustained release indapamide: results of randomized double – blind controlled studies. J Hypertension 1998; 16: 1677–84.

11. Donnely R. Clinical implications of indapamide sustained release 1,5 mg in hypertension. Clin Pharmacokinetics 1999; 37 (Suppl. 1): 21–32.

12. Emerian J-P, Knauf H, Puja Las J.O. A comparison of indapamide SR 1,5 mg with both amlodipine 5 mg and hydrochlirothiazide 25 mg in eldery hypertensive patients: a randomized double – blind controlled study. J Hypertension 2001; 19: 343–50.

13. Cooper R.S, Simmons B.E, Castaner A et al. Left ventricular hypertrophy is associated with worse survival in independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990; 65: 441–5.

14. Gosse P, Sheridan D.J, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertension 2000; 18: 1465–75.

15. Marre M, Puig J.G, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertension 2004; 22: 1613–22.

16. Weidmann P. Metabolic profile of indapamide sustained – release in patients with hypertension. Drug safety 2001; 24: 1155–65.


Для цитирования:

Чазова И.Е. Эффективность и безопасность современных мочегонных препаратов у пациентов с артериальной гипертонией осложненного течения. Системные гипертензии. 2005;(1):39-42.

Просмотров: 29

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)